Login to Your Account



And Maybe More

Ovarian Trial 'MEKs' Big Year: Array Rolls Out Five Phase IIIs

By Randy Osborne
Staff Writer

Wednesday, May 8, 2013
Array BioPharma Inc.'s Phase III trial planned for this summer in recurrent low-grade serous ovarian cancer (LGSOC) with its Novartis AG-partnered MEK inhibitor is one of a handful of late-stage studies expected to roll out this year.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription